BRAF V600E-mutant non-small-cell lung cancer

What changed: BRAF V600E-mutant non-small-cell lung cancer

Every dated change on the records linked to BRAF V600E-mutant non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Regulatory1Trial result1Milestone3This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordBRAF V600E-mutant non-small-cell lung cancer
Facts on this page last checked
When this page itself was last checked or edited.

October 2023 · 1

2023-10-11RegulatoryEncorafenib
Encorafenib: approval (US)
BRAF V600E NSCLC with binimetinib

2023 · 2

2017 · 1

2017MilestoneDabrafenib + trametinib
Dabrafenib plus trametinib approved for BRAF V600E lung cancer after BRF113928
A milestone in how this cancer is treated.

2014 · 1

2014ApprovalDabrafenib
Dabrafenib approved in US
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma

2002 · 1

2002MilestoneBRAF
BRAF V600E mutations discovered across cancers, including a small share of lung cancers
A milestone in how this cancer is treated.